IBD targets move beyond TNF
IL-23, S1P modulators, and oral options are reshaping inflammatory bowel disease therapy choice.
Inflammatory bowel disease care is no longer a TNF-first conversation in every patient. With IL-23 antagonists, S1P modulators, and oral options, sequencing is becoming the central clinical question.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is lupus nephritis?
- ExplainedWhat is Sjogren disease?
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.